October 17, 2005
Vancouver, Canada – iCo Therapeutics Inc. announced today that Andrew Rae, iCo’s Chief Executive Officer, will present at the BIO InvestorForum to be held October 19-20th, 2005 in San Francisco, California. Approximately 190 public and venture-stage companies are slated to present at this conference which is being hosted by the Biotechnology Industry Organization.
Mr. Rae’s presentation will take place on October 20th, 2005 at 12:20pm PST in the Sea Cliff room at the Palace Hotel in San Francisco. For more information about the conference, visit the BIO InvestorForum website.
iCo seeks out and develops or modifies approved or near-approved therapies to treat a variety of conditions within isolated biological environments. Because the drugs have already been through extensive preclinical and clinical testing, and in some cases regulatory approval, development risk and time to commercialization is significantly decreased.
About iCo Therapeutics, Inc.
iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology company focused on developing pre-existing drugs for a range of new conditions affecting isolated biological environments – areas such as the eye, spinal cord, or joints – where locally-administered application of these therapies would have minimal systemic distribution and fewer safety issues.
For more information, visit the company website at: https://icotherapeutics.com.
Business Development Contact:
Dr. John Clement, CTO
Mr. John Meekison, CFO